These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2575315)

  • 1. Effect of N-ethylmaleimide treatment on naloxone binding in frog brain membranes.
    Zawilska J; Lajtha A; Borsodi A
    Acta Biochim Biophys Hung; 1989; 24(1-2):33-9. PubMed ID: 2575315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective protection of benzomorphan binding sites against inactivation by N-ethylmaleimide. Evidence for kappa-opioid receptors in frog brain.
    Zawilska J; Lajtha A; Borsodi A
    J Neurochem; 1988 Sep; 51(3):736-9. PubMed ID: 2900875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
    Tam SW; Liu-Chen LY
    J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of kappa opioid receptors by N-ethylmaleimide.
    Borsodi A; Zawilska J; Lajtha A
    Prog Clin Biol Res; 1990; 328():89-92. PubMed ID: 2154825
    [No Abstract]   [Full Text] [Related]  

  • 5. Anatomical distribution of sodium-dependent [(3)H]naloxone binding sites in rat brain.
    Sim-Selley LJ; Xiao R; Childers SR
    Synapse; 2000 Mar; 35(4):256-64. PubMed ID: 10657035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of opiate receptor binding sites and guanine nucleotide regulatory sites: selective protection from N-ethylmaleimide.
    Childers SR
    J Pharmacol Exp Ther; 1984 Sep; 230(3):684-91. PubMed ID: 6088761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characterization of opioid receptor from bullfrog brain].
    Makimura M; Ito Y; Murakoshi Y
    Yakubutsu Seishin Kodo; 1988 Jun; 8(2):359-66. PubMed ID: 2851236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3H]dynorphin1-8 binding sites in frog (Rana esculenta) brain membranes.
    Benyhe S; Simon J; Borsodi A; Wollemann M; Barnard EA
    Neuropeptides; 1994 May; 26(5):359-64. PubMed ID: 7915022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Binding sites of opiates and endogenous opioids in the oocytes of the toad Bufo viridis].
    Bakalkin GIa; Iakovleva TV; Korobov KP; Bespalova ZhD; Vinogradov VA
    Biokhimiia; 1984 Jun; 49(6):883-8. PubMed ID: 6087934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [D-Pro10]-dynorphin(1-11) is a kappa-selective opioid analgesic in mice.
    Gairin JE; Gout R; Meunier JC; Cros J
    J Pharmacol Exp Ther; 1988 Jun; 245(3):995-1001. PubMed ID: 2898527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of high-affinity 3H-opioid binding. Further evidence for Mu1 sites.
    Nishimura SL; Recht LD; Pasternak GW
    Mol Pharmacol; 1984 Jan; 25(1):29-37. PubMed ID: 6323950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Method for isolation of kappa-opioid binding sites by dynorphin affinity chromatography.
    Simon J; Benyhe S; Hepp J; Varga E; Medzihradszky K; Borsodi A; Wollemann M
    J Neurosci Res; 1990 Apr; 25(4):549-55. PubMed ID: 1972199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arachidonic acid modulation of [3H]naloxone specific binding to rat brain opioid receptors.
    Oktem HA; Apaydin S
    Neurobiology (Bp); 1998; 6(3):323-32. PubMed ID: 9778651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Opiate receptor binding of naloxone in the rat brain: effect of sodium ions].
    Balashov AM; Petrichenko OB; Aliab'eva TN; Panchenko LF
    Biokhimiia; 1988 Sep; 53(9):1527-31. PubMed ID: 2849481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating aspects of opioid receptor binding by [3H](-) (1R,5R,9R,2''S)-5,9-dimethyl-2-tetrahydrofurfuryl-2'-hydroxy-6,7- benzomorphan hydrochloride ([3H]Mr 2034), a drug preferentially acting on kappa-receptors.
    Ensinger HA
    Arzneimittelforschung; 1985; 35(1A):447-51. PubMed ID: 2985096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium regulation of agonist binding at opioid receptors. I. Effects of sodium replacement on binding at mu- and delta-type receptors in 7315c and NG108-15 cells and cell membranes.
    Puttfarcken P; Werling LL; Brown SR; Cote TE; Cox BM
    Mol Pharmacol; 1986 Aug; 30(2):81-9. PubMed ID: 3016503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of receptor-mediated inhibition of adenylate cyclase in NG108-15 neuroblastoma X glioma cells by n-ethylmaleimide.
    Smith MM; Harden TK
    J Pharmacol Exp Ther; 1984 Feb; 228(2):425-33. PubMed ID: 6319678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.